Latest Breaking News On - Life science alliance - Page 4 : comparemela.com

Santhera Receives Approval for AGAMREE® (Vamorolone) as a

Approval by the Medicines and Healthcare products Regulatory Agency (MHRA) of AGAMREE® in the United Kingdom follows marketing authorization for this.

United statesUnited kingdomSwitzerland generalShabir hashamEva kaliasEuropean medicines agencyAmerica to catalyst pharmaceuticalsEuropean unionLife science allianceHead investor relations communicationsRegulatory agencySanthera pharmaceuticals holdingSanthera pharmaceuticalsDuchenne research fundEnergyx ray absorptiometryEuropean commission

Santhera s AGAMREE (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophy

Santhera’s AGAMREE (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophy

United kingdomSwitzerland generalUnited statesElizabeth vroomDario eklundCatalyst pharmaceuticalsWorld duchenne organizationCommittee for medicinal products human useEuropean commissionLife science allianceAmerica to catalyst pharmaceuticalsRegulatory agencyEuropean unionSanthera pharmaceuticalsEnergyx ray absorptiometryEuropean medicines agency

Researchers identify protein with DYRK1A-inhibiting effect that may have implications for Down syndrome

Researchers identify protein with DYRK1A-inhibiting effect that may have implications for Down syndrome
phys.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phys.org Daily Mail and Mail on Sunday newspapers.

Yoshihiko miyataKyoto universityLife science allianceGraduate schoolLife science

Santhera s AGAMREE® (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophy

European Commission (EC) grants marketing authorization for AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and olderAGAMREE® is the only approved medication in the European Union (EU) for treating DMD, and the first DMD treatment approved in both the U.S. and EUFirst commercial launch of AGAMREE®, in Germany, expected in Q1-2024 EMA acknowledges safety benefits of AGAMREE® with regards to preserving bone health and maintaining growth compared to standard

United kingdomSwitzerland generalUnited statesElizabeth vroomDario eklundEva kaliasEnergyx ray absorptiometryCommittee for medicinal products human useEuropean unionSanthera pharmaceuticalsWorld duchenne organizationHead investor relations communicationsDrug administrationEuropean medicines agencyCatalyst pharmaceuticalsLife science alliance

Early epigenetic instructions anticipate next steps of gene activity during blood cell development

Early epigenetic instructions anticipate next steps of gene activity during blood cell development
phys.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phys.org Daily Mail and Mail on Sunday newspapers.

Alexander maytumConstanze boniferJean baptiste cazierLife science allianceInstitute of cancerNature communicationsUniversity of birminghamProfessor constanze boniferProfessor jean baptiste cazier